Literature DB >> 25038581

Tumoral reprogramming: Plasticity takes a walk on the wild side.

Elena Campos-Sánchez1, César Cobaleda2.   

Abstract

Cellular plasticity is the capacity that cells have to change their fate and adopt a new identity. Plasticity is essential for normal development and for tissue regeneration and, in an experimental setting, for the induction of pluripotency. All these processes involve a reprogramming of the cellular identity, mediated by signals from the environment and/or by internal changes at the transcriptional and epigenetic levels. Tumorigenesis is a process in which normal cells acquire a new malignant identity and give rise to a clonal aberrant population. This is only possible if the initiating cell has the necessary plasticity to undergo such changes, and if the oncogenic event(s) initiating cancer has the essential reprogramming capacity so as to be able to lead a change in cellular identity. The molecular mechanisms underlying tumoral reprogramming are the pathological counterparts of the normal processes regulating developmental plasticity or experimentally-induced reprogramming. In this review we will first revise the main features of non-pathological examples of reprogramming, and then we will describe the parallelisms with tumoral reprogramming, and we will also delineate how the precise knowledge of the reprogramming mechanisms offers the potential for the development of new therapeutical interventions. This article is part of a Special Issue entitled: Stress as a fundamental theme in cell plasticity.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer reprogramming; Cancer stem cells; Induced pluripotency; Plasticity; iPSCs

Mesh:

Year:  2014        PMID: 25038581     DOI: 10.1016/j.bbagrm.2014.07.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Stemness in Liver Cancer.

Authors:  Snorri S Thorgeirsson
Journal:  Dig Dis       Date:  2017-05-03       Impact factor: 2.404

Review 2.  Metabostemness: a new cancer hallmark.

Authors:  Javier A Menendez; Tomás Alarcón
Journal:  Front Oncol       Date:  2014-09-29       Impact factor: 6.244

Review 3.  Cellular reprogramming for understanding and treating human disease.

Authors:  Riya R Kanherkar; Naina Bhatia-Dey; Evgeny Makarev; Antonei B Csoka
Journal:  Front Cell Dev Biol       Date:  2014-11-12

4.  Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance.

Authors:  Gina Lee; Robert R Hall; Atique U Ahmed
Journal:  J Stem Cell Res Ther       Date:  2016-10-26

Review 5.  The plasticity of germ cell cancers and its dependence on the cellular microenvironment.

Authors:  Daniel Nettersheim; Hubert Schorle
Journal:  J Cell Mol Med       Date:  2017-02-28       Impact factor: 5.310

6.  Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG.

Authors:  Christina Wefers; Gerty Schreibelt; Leon F A G Massuger; I Jolanda M de Vries; Ruurd Torensma
Journal:  Front Immunol       Date:  2018-06-19       Impact factor: 7.561

7.  Cancer Stem Cells: Emergent Nature of Tumor Emergency.

Authors:  Yaroslav R Efremov; Anastasia S Proskurina; Ekaterina A Potter; Evgenia V Dolgova; Oksana V Efremova; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Front Genet       Date:  2018-11-16       Impact factor: 4.599

Review 8.  Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment.

Authors:  Hao-Ran Sun; Shun Wang; Shi-Can Yan; Yu Zhang; Peter J Nelson; Hu-Liang Jia; Lun-Xiu Qin; Qiong-Zhu Dong
Journal:  Front Oncol       Date:  2019-10-24       Impact factor: 6.244

Review 9.  Extracellular Vesicles as Drug Delivery Systems in Cancer.

Authors:  Laia Hernandez-Oller; Joaquin Seras-Franzoso; Fernanda Andrade; Diana Rafael; Ibane Abasolo; Petra Gener; Simo Schwartz
Journal:  Pharmaceutics       Date:  2020-11-26       Impact factor: 6.321

Review 10.  Potential of epigenetic therapies in the management of solid tumors.

Authors:  Victor Valdespino; Patricia M Valdespino
Journal:  Cancer Manag Res       Date:  2015-07-31       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.